ERBB2 and cancer: In our previous studies, H2-18, an ErbB2 domain I-specific fully human antibody, exhibited a greater antitumor effect than trastuzumab and pertuzumab, either alone or in combination, in innate trastuzumab resistant cancer cell lines [11, 12].